INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ind-Swift Laboratories has filed a Nil Statement confirming no deviation in the use of funds raised via a Preferential Issue of Convertible Warrants. Rs. 255.61 crore was raised (out of a total issue size of Rs. 314.60 crore). As of 31 March 2026, Rs. 232.02 crore has been utilized — Rs. 89.95 crore on business expansion, Rs. 27.47 crore on subsidiary investments, Rs. 39.60 crore on working capital, and Rs. 75 crore on general corporate purposes. Notably, warrants allotted to SARAL INCORPORATED VCC SUB FUND 1 (Rs. 58.99 crore) have become non-receivable after the conversion tenure expired in February 2026, reducing the realizable proceeds. Essix Biosciences Limited contributed Rs. 46.28 crore during Q4. CARE Ratings is the monitoring agency.
The company has confirmed proper use of funds with no deviation. However, the non-realization of Rs. 58.99 crore from SARAL reduces the total available proceeds, which may affect the originally planned expansion and investment plans.